170 related articles for article (PubMed ID: 17531130)
1. Post-transplant lymphoproliferative disorder treated with rituximab: case report.
Meng HT; Li Y; Liu JH; Xu GX; Teng XD
Chin Med J (Engl); 2007 May; 120(9):841-3. PubMed ID: 17531130
[No Abstract] [Full Text] [Related]
2. Primary nonresponse to anti-cd20 therapy in gastrointestinal posttransplant lymphoproliferative disorder.
Gökçe S; Süoğlu OD; Sökücü S; Gün F; Emiroğlu H; Celik A; Doğan O; Cevikbaş U
J Pediatr Gastroenterol Nutr; 2006 Mar; 42(3):316-20. PubMed ID: 16540802
[No Abstract] [Full Text] [Related]
3. Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation.
Cornejo A; Bohnenblust M; Harris C; Abrahamian GA
Cancer Chemother Pharmacol; 2009 Sep; 64(4):857-60. PubMed ID: 19588139
[TBL] [Abstract][Full Text] [Related]
4. Post-transplant lymphoproliferative disorder with Hodgkin's lymphoma and large B-cell lymphoma differentiation.
Novoa-Takara L; Dincer A; Kampalath B; Van Tuinen P; Hariharan S; Chang C
Histopathology; 2005 Sep; 47(3):333-4. PubMed ID: 16115242
[No Abstract] [Full Text] [Related]
5. Monoclonal antibody therapy for posttransplant lymphoproliferative disorders.
Habermann TM
Liver Transpl; 2000 Sep; 6(5):657-8. PubMed ID: 10980069
[No Abstract] [Full Text] [Related]
6. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
Svoboda J; Kotloff R; Tsai DE
Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
Garceau P; Couture C; Cantin B; Bernier V; Sénéchal M
J Heart Lung Transplant; 2008 Aug; 27(8):928-31. PubMed ID: 18656811
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of intraocular post-transplant lymphoproliferative disorder with intravenous rituximab.
Iu LP; Yeung JC; Loong F; Chiang AK
Pediatr Blood Cancer; 2015 Jan; 62(1):169-72. PubMed ID: 25174958
[TBL] [Abstract][Full Text] [Related]
9. High-intensity chemotherapy and rituximab for the treatment of posttransplant lymphoproliferative disorder.
Chen RW; Sweetenham JW
Am J Clin Oncol; 2006 Apr; 29(2):211-2. PubMed ID: 16601446
[No Abstract] [Full Text] [Related]
10. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation.
Zilz ND; Olson LJ; McGregor CG
J Heart Lung Transplant; 2001 Jul; 20(7):770-2. PubMed ID: 11448808
[TBL] [Abstract][Full Text] [Related]
11. PTLD treatment: reducing the chemotherapy burden through addition of rituximab.
Dharnidharka VR; Gupta S
Pediatr Transplant; 2010 Feb; 14(1):10-1. PubMed ID: 20078838
[No Abstract] [Full Text] [Related]
12. Rituximab with peripheral blood stem cell transplantation in CD20 lymphoproliferative disorders.
Mazza P; Palazzo G; Amurri B; Pricolo G; Prudenzano A; Stani L
Haematologica; 2001 Oct; 86(10):1104-5. PubMed ID: 11602420
[No Abstract] [Full Text] [Related]
13. Bone marrow necrosis complicating post-transplant lymphoproliferative disorder: resolution with rituximab.
Rossi D; Ramponi A; Franceschetti S; Stratta P; Gaidano G
Leuk Res; 2008 May; 32(5):829-34. PubMed ID: 18036657
[TBL] [Abstract][Full Text] [Related]
14. Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation?
Oertel SH; Anagnostopoulos I; Bechstein WO; Liehr H; Riess HB
Transplantation; 2000 Feb; 69(3):430-2. PubMed ID: 10706055
[TBL] [Abstract][Full Text] [Related]
15. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation.
Lee JJ; Lam MS; Rosenberg A
Ann Pharmacother; 2007 Oct; 41(10):1648-59. PubMed ID: 17848421
[TBL] [Abstract][Full Text] [Related]
16. CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab.
Ifthikharuddin JJ; Mieles LA; Rosenblatt JD; Ryan CK; Sahasrabudhe DM
Am J Hematol; 2000 Oct; 65(2):171-3. PubMed ID: 10996837
[TBL] [Abstract][Full Text] [Related]
17. Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child.
Hayashida M; Ogita K; Matsuura T; Takahashi Y; Nishimoto Y; Ohga S; Hara T; Soejima Y; Taketomi A; Maehara Y; Kohashi K; Tsuneyoshi M; Taguchi T
Pediatr Transplant; 2007 Sep; 11(6):671-5. PubMed ID: 17663692
[TBL] [Abstract][Full Text] [Related]
18. Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kidney transplant recipient with posttransplant lymphoproliferative disease.
Pham PT; Wilkinson AH; Gritsch HA; Pham PC; Miller JM; Lassman CR; Danovitch GM
Transplant Proc; 2002 Jun; 34(4):1178-81. PubMed ID: 12072308
[No Abstract] [Full Text] [Related]
19. Usefulness and limitations of rituximab in managing patients with lymphoproliferative disorder after heart transplantation.
Senechal M; Demers S; Cantin B; Bourgault C; Leblanc MH; Morin J; Couture C
Exp Clin Transplant; 2012 Oct; 10(5):513-8. PubMed ID: 22747415
[TBL] [Abstract][Full Text] [Related]
20. Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus.
Kaposztas Z; Etheridge WB; Kahan BD
Transplant Proc; 2008 Jun; 40(5):1744-6. PubMed ID: 18589184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
